Can flickering lights and tones slow Alzheimer's? MIT trial begins
NCT ID NCT04055376
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether using a device that delivers light and sound stimulation for 60 minutes each day is safe and practical for people with mild Alzheimer's. Fifteen participants will use the device at home for 6 to 9 months. The main goals are to see if people can stick with the daily routine and if any side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- GENUS device (light and sound stimulation)
- What this could lead to
- If it works, this could point toward a non-drug way to ease Alzheimer's symptoms at home.
- What could go wrong
- This is a very small, early feasibility trial with only 15 people. It focuses on safety and device use, not yet on whether it truly helps memory or thinking.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
15 people
The number who actually took part.
- Started
-
Aug 2019
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subject is between the ages of 50 - 100. * Subject must have mild Alzheimer's disease with a Mini Mental State Exam (MMSE) score of 19 -26. * Subject is willing to sign informed consent document. * If subject is deemed to not have capacity to sign the informed consent, he/she will need a legally authorized representative to provide surrogate consent. * Subjects whose primary residence is within 2 hours of Boston * Able to complete the 1st month of at home stimulation at their primary residence; if subjects plan to spend more than 1 week away from their primary residence during the trial, their inclusion must be assessed by the research team. Exclusion Criteria: * Subjects who do not have healthcare. * Subjects who are being treated with N-methyl-D-aspartate (NMDA) receptor antagonists (eg. Memantine). * Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc. * Subjects with history of seizure or epilepsy within the past 24 months. * Subjects with clinically significant suicide risk and/or suicide attempt in the past 12 months. * Subjects with behavioral problems such as aggression/agitation/impulsivity that might interfere with their ability to comply with protocol. * Active treatment with one or more anti-epileptic agent. * Subjects who have had a stroke within the past 24 months. * Subjects diagnosed with migraine headache. * Active treatment with one or more psychiatric agent (e.g. antidepressants, antipsychotics, etc). * Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and/or sacral nerve stimulator. * Subjects who have profound hearing or visual impairment. * Subjects who have a life expectancy of less than 24 months. * Subjects who are pregnant.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer dementia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts Institute of Technology
Cambridge, Massachusetts, 02139, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Can a gentle electric current calm the mind in Alzheimer's?
- Alzheimer's vaccine aims to clear amyloid before memory fades
- Blood, eye, and brain scans team up to spot Alzheimer's earlier
- Can a home device slow Alzheimer's? pilot study tests pulsed electromagnetic therapy
- Eye scans as a window to the body: study probes retinal imaging across diseases